Skip to main content
Top
Published in: Diabetologia 7/2006

01-07-2006 | Short communication

Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods

Authors: R. J. MacIsaac, C. Tsalamandris, M. C. Thomas, E. Premaratne, S. Panagiotopoulos, T. J. Smith, A. Poon, M. A. Jenkins, S. I. Ratnaike, D. A. Power, G. Jerums

Published in: Diabetologia | Issue 7/2006

Login to get access

Abstract

Aims/hypothesis

We compared the predictive performance of a GFR based on serum cystatin C levels with commonly used creatinine-based methods in subjects with diabetes.

Subjects, materials and methods

In a cross-sectional study of 251 consecutive clinic patients, the mean reference (plasma clearance of 99mTc-diethylene-triamine-penta-acetic acid) GFR (iGFR) was 88±2 ml min−1 1.73 m−2. A regression equation describing the relationship between iGFR and 1/cystatin C levels was derived from a test population (n=125) to allow for the estimation of GFR by cystatin C (eGFR-cystatin C). The predictive performance of eGFR-cystatin C, the Modification of Diet in Renal Disease 4 variable formula (MDRD-4) and Cockcroft–Gault (C–G) formulas were then compared in a validation population (n=126).

Results

There was no difference in renal function (ml min−1 1.73 m−2) as measured by iGFR (89.2±3.0), eGFR-cystatin C (86.8±2.5), MDRD-4 (87.0±2.8) or C–G (92.3±3.5). All three estimates of renal function had similar precision and accuracy.

Conclusions/interpretation

Estimates of GFR based solely on serum cystatin C levels had the same predictive potential when compared with the MDRD-4 and C–G formulas.
Literature
1.
go back to reference Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A (2005) Cystatin C as a marker of GFR history, indications, and future research. Clin Biochem 38:1–8PubMedCrossRef Filler G, Bokenkamp A, Hofmann W, Le Bricon T, Martinez-Bru C, Grubb A (2005) Cystatin C as a marker of GFR history, indications, and future research. Clin Biochem 38:1–8PubMedCrossRef
2.
go back to reference Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18:2024–2031PubMedCrossRef Hoek FJ, Kemperman FA, Krediet RT (2003) A comparison between cystatin C, plasma creatinine and the Cockcroft and Gault formula for the estimation of glomerular filtration rate. Nephrol Dial Transplant 18:2024–2031PubMedCrossRef
3.
go back to reference Premaratne E, MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith T, Jerums G (2005) Renal hyperfiltration in type 2 diabetes: effect of age related decline in GFR. Diabetologia 48:2486–2493PubMedCrossRef Premaratne E, MacIsaac RJ, Tsalamandris C, Panagiotopoulos S, Smith T, Jerums G (2005) Renal hyperfiltration in type 2 diabetes: effect of age related decline in GFR. Diabetologia 48:2486–2493PubMedCrossRef
4.
go back to reference Mathew T on behalf of the Australasian Creatinine Consensus Working Group (2005) Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 183:138–141PubMed Mathew T on behalf of the Australasian Creatinine Consensus Working Group (2005) Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust 183:138–141PubMed
5.
go back to reference Jenkins MA, Brown DJ, Ierino FL, Ratnaike SI (2003) Cystatin C for estimation of glomerular filtration rate in patients with spinal cord injury. Ann Clin Biochem 40:364–368PubMedCrossRef Jenkins MA, Brown DJ, Ierino FL, Ratnaike SI (2003) Cystatin C for estimation of glomerular filtration rate in patients with spinal cord injury. Ann Clin Biochem 40:364–368PubMedCrossRef
6.
go back to reference Manjunath G, Sarnak MJ, Levey AS (2001) Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 10:785–792PubMedCrossRef Manjunath G, Sarnak MJ, Levey AS (2001) Prediction equations to estimate glomerular filtration rate: an update. Curr Opin Nephrol Hypertens 10:785–792PubMedCrossRef
7.
go back to reference Poggio ED, Wang X, Greene T, Van Lente F, Hall PM (2005) Performance of the modification of diet in renal disease and Cockcroft–Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16:459–466PubMedCrossRef Poggio ED, Wang X, Greene T, Van Lente F, Hall PM (2005) Performance of the modification of diet in renal disease and Cockcroft–Gault equations in the estimation of GFR in health and in chronic kidney disease. J Am Soc Nephrol 16:459–466PubMedCrossRef
8.
go back to reference Perkins BA, Nelson RG, Ostrander BE et al (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404–1412PubMedCrossRef Perkins BA, Nelson RG, Ostrander BE et al (2005) Detection of renal function decline in patients with diabetes and normal or elevated GFR by serial measurements of serum cystatin C concentration: results of a 4-year follow-up study. J Am Soc Nephrol 16:1404–1412PubMedCrossRef
9.
go back to reference Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K (2003) Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 42:36–43PubMedCrossRef Wasen E, Isoaho R, Mattila K, Vahlberg T, Kivela SL, Irjala K (2003) Serum cystatin C in the aged: relationships with health status. Am J Kidney Dis 42:36–43PubMedCrossRef
10.
go back to reference Shlipak MG, Sarnak MJ, Katz R et al (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRef Shlipak MG, Sarnak MJ, Katz R et al (2005) Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 352:2049–2060PubMedCrossRef
Metadata
Title
Estimating glomerular filtration rate in diabetes: a comparison of cystatin-C- and creatinine-based methods
Authors
R. J. MacIsaac
C. Tsalamandris
M. C. Thomas
E. Premaratne
S. Panagiotopoulos
T. J. Smith
A. Poon
M. A. Jenkins
S. I. Ratnaike
D. A. Power
G. Jerums
Publication date
01-07-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 7/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0275-7

Other articles of this Issue 7/2006

Diabetologia 7/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.